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Summary Cardiac function was evaluated in 86 breast cancer patients after standard chemotherapy, followed by ablative chemotherapy and
chest irradiation. One patient died of subacute heart failure 3 months after ablative chemotherapy. At a minimum of 1 year's follow-up (range
1-11 years) left vertricular ejection fraction (LVEF) was marginally abnormal in 4 of 27 disease-free survivors. One exceptional patient who
received two transplantations is alive, with serious heart failure occurring after the second ablative chemotherapy. Including this patient, the
percentage of patients free of clinical and subclinical cardiac dysfunction at 7 years is 78% (95% Cl 61-95%). After ablative chemotherapy,
cardiotoxicity was rarely life-threatening. The impact of subclinical cardiotoxicity in the long term is not clear and needs continued evaluation.
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Intensive chemotherapy, which we have defined by induction
chemotherapy followed by ablative chemotherapy with bone
marrow or stem cell rescue, combined with radiotherapy is, at
present, a usual treatment for patients with locally advanced or
disseminated breast cancer (Triozzi et al, 1995). Many chemother-
apeutic drugs and radiotherapy have toxic effects on the heart. The
anthracyclines are notorious for their cumulative cardiotoxicity
(Von Hoff et al, 1979; Cornbleet et al, 1984; Nielsen et al, 1990).
Late cardiotoxicity can occur more than 1 year after drug exposure
(Rhoden et al, 1993; Steinherz et al, 1995). Subacute cardiotoxi-
city is considered to be reversible, whereas late effects are consid-
ered to be lasting and progressive with time (Cohen et al, 1982;
Saini et al, 1987; Shapiro and Henderson, 1994). Radiation-
induced heart disease (RIHD) includes late congestive heart
failure (CHF) or coronary artery disease (Totterman et al, 1983;
Cuzick et al, 1994; Gyenes et al, 1994; Stewart et al, 1995). The
risk ofRIHD is related to the total radiation dose and the irradiated
volume (Steinherz and Yahalom, 1993; Gyenes et al, 1994). There
are reports that left-sided chest irradiation causes more cardio-
toxicity than right-sided irradiation (Rutqvist et al, 1992).
Data about late cardiotoxic effects of intensive chemotherapy,
combined with radiotherapy in the treatment of breast cancer, are
limited. Therefore, we have evaluated the cardiac function in
breast cancer patients several years after standard-dose doxo-
rubicin- or epirubicin-based induction therapy, followed by
cyclophosphamide- or mitoxantrone-based ablative therapy and
irradiation. Cardiac function was evaluated by measuring left
ventricular ejection fraction (LVEF) by means of a radionuclide
angiography, because it is still considered to be the standard
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non-invasive method for detecting cardiotoxicity (McKillop et al,
1983; Druck et al, 1984; John et al, 1988).
PATIENTS AND METHODS
Eighty-six premenopausal patients with locally advanced or
disseminated breast cancer were treated with intensive (induction
and ablative) chemotherapy supported by bone marrow or stem
cell rescue and radiotherapy between 1984 and 1994. Before treat-
ment, none of the patients had manifest signs or symptoms of
cardiac disease. Fifty-two patients (60%) were alive at the start of
a cardiac evaluation in September 1994. Cardiac function was
assessed in 27 of these 52 patients, who were more than 1 year in
follow-up after completing intensive chemotherapy. The median
follow-up ofthe study group was 2 years (range 1-11 years); their
median age was 42 years (range 28-54 years).
Thechemotherapy consisted ofdoxorubicin- orepirubicin-based
standard induction chemotherapy, followed by cyclophosphamide-
or mitoxantrone-based ablative chemotherapy. Twenty-four
patients received a cumulative dose of doxorubicin of 300 mg m-2
intravenously (De Graaf et al, 1994). Three patients received a
cumulative dose ofepirubicin of480 mg m-2. Six patients received
a cyclophosphamide-based ablative regimen with a cumulative
dose of 7 g m-2 cyclophosphamide given intravenously over three
consecutive days in combination with 1.5 g m-2 etoposide (CE).
Twenty patients received a mitoxantrone-based ablative regimen:
in 14 patients, 50 mg m-2 mitoxantrone was combined with
800 mg m-2 thiotepa (MT); in three patients, 60 mg m-2 mito-
xantrone was combined with 180 mg m-2 melphalan (MM); and in
three patients, 800 mg m-2 thiotepa (TMM) was added. One patient
had both CE and the TMM regimen.
Seventeen of20 patients with locally advanced disease received
50-66 Gy locoregional radiotherapy a median of 11 weeks (range
8-19) after the ablative chemotherapy. In four ofthese 17 patients,
this was part of a breast-conserving treatment. Of seven patients
with disseminated disease, six received radiotherapy - four as
primary treatment before chemotherapy and two patients after the
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Table 1 Effect of ablative chemotherapy (after pretreatment with
anthracycline-based induction chemotherapy) on LVEF of 26 breast cancer
patients without clinically manifest cardiotoxicity
Ablative chemotherapy Number of Abnormal
patients LVEF (<55%)
n(%)
CE 6 1 (17)
MT 14 1 (7)
MM 3 1 (33)
TMM 3 1 (33)
Total 26 4
CE, cyclophosphamide 7 g m-2 + etoposide 1.5 g m-2; MT, mitoxantrone
50 mg m-2 + thiotepa 800 mg m-2; MM, mitoxantrone 60 mg m-2 + melphalan
180 mg m-2; TMM, mitoxantrone 60 mg m-2 + melphalan 180 mg m-2 +
thiotepa 800 mg m-2.
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Figure 2 Overall survival in 86 patients treated with high-dose
chemotherapy and radiotherapy. The median observation (arrow) is
24 months. The overall survival at 84 months is 45% (95% Cl 33-58%)
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Figure 1 Percentage of patients free of clinical and subcl
dysfunction out of 86 patients treated with high-dose chemi
radiotherapy. The median observation (arrow) is 24 months
of patients free of cardiac dysfunction at 84 months is 78%
ablative chemotherapy. In all cases irradiation was
MeV photons from a linear accelerator in fraction
breast or chest wall, the supraclavicular, axilla
mammary lymph nodes. The internal mammary lyi
irradiated by a direct anterior field after amput
wedged tangential field forbreast-conserving treat
Cardiac evaluation consisted ofclinical functior
according to the New York Heart Association (N
12-lead electrocardiogram (ECG) and left vent
fraction (LVEF) by ECG-gated radionuclide angic
calculation of the LVEF, 400-MBq 99-Tc-labelled
blood cells were injected and acquisition was pern
with a large-field-of-view gamma-camera with a
purpose parallel-hole collimator. A LVEF of < 5'
cut-offvalue in our hospital.
Statistical analysis was performed by the chi-s
Haenszel) and Fisher exact test, and survival cun
using the Kaplan-Meier method.
RESULTS
Of the 86 patients who were treated with intensiv
and irradiation forbreast cancer, 34 had died befor
cardiac evaluation in September 1994, leaving 52
In one ofthesepatients, the cause ofdeath was subacute cardiotox-
icity 3 months after the ablative chemotherapy. This concerned a
42-year-old patient treated with cumulative 300 mg m-2 doxoru-
bicin and 50 mg m-2 mitoxantrone without radiotherapy, who was
admitted to the hospital because of rapidly progressive CHF. The
echocardiogram showed a markedly decreased contractility,
withoutpericardial effusion. She had no pre-existing heart disease.
Post-mortem examination was denied.
One ofthe 27 patients received adouble transplant with a4-year
60 72 84 interval. She developed heart failure 2 weeks after her second
transplant. The LVEF dropped from 58% to 13%. With diuretics,
15 11 2 digoxin, dobutamine and an ACE inhibitor, the clinical situation is
stable and acceptable at this moment (2 years later). Functionally,
linical cardiac she is categorized as stage III NYHA.
iotherapy and The other 26 patients had no clinical signs or symptoms of s.The percentage
(95% Cl 61-95%) cardiotoxicity (NYHA classification I). The QTc interval was
normal in all 26 patients. The LVEF was slightly abnormal in
four patients treated with TMM, MT, MM and CE ablative
s given with 4-6 chemotherapy (50% in one and 52% in three patients) after 1, 3, 6
Is of 2 Gy to the and 7 years follow-up respectively (Table 1). The abnormal LVEF
ry and internal occurred in two patients after left- and, in two, after right-sided
mph nodes were irradiation. Because of this small number, no conclusions on the
tation and by a influence of left- vs right-sided irradiation or the effect of
tment. combination radio-chemotherapy is possible. We estimated the
ial classification percentage ofpatients free ofcardiac dysfunction at S and 7 years,
YHA), standard adding the two clinical and four subclinical events. As shown in
tricular ejection Figure 1, at 5 years the estimated percentage of patients free of
)graphy. For the cardiac dysfunction is 94% (95% CI 88-100%) and at 7 years 78%
[autologous red (95% CI 61-95%) (Figure 1). The overall survival is shown in
formed in 6 min Figure 2.
low-energy all-
5% is the lower DISCUSSION
square (Mantel- In the treatment of breast cancer, in most cases, a combination of
ves were plotted chemotherapy and radiotherapy is used. In patients treated with
'standard' adjuvant chemotherapy with a cumulative dose of
300 mg m-2 doxorubicin and left-sided irradiation, 2.6% CHF was
found after a median follow-up of 6.5 years, compared with 0.3%
CHF forright-sided or no irradiation (Valagussa et al, 1994).
,e chemotherapy Little is known about the acute and late cardiotoxic effects of
e the start ofthe intensive chemotherapy, which represents a cumulative effect of
patients at risk. standard and ablative chemotherapy, and of its combination with
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chest irradiation. All ablative regimens were based on
cyclophosphamide (CE) or mitoxantrone (MT, MM or TMM).
Cyclophosphamide can induce acute cardiotoxicity, especially in
children, but it is unclear whether it can cause late cardiotoxicity
(Gottdiener et al, 1981; Steinherz and Yahalom, 1993). In 18
adults with haematological diseases (mean age 35 years) treated
with high-dose cyclophosphamide (5.5-8 g m-2), only one patient
(5.5%) developed a mild CHF with decrease of LVEF to 40%
(Braverman et al, 1991). For the CE combination, we have
reported the results of a phase I study using 7 g m-2 cyclophos-
phamide and 2-2.5 g m-2 etoposide without radiotherapy. No acute
cardiotoxicity was observed in six patients (Mulder et al, 1984).
Mitoxantrone given after anthracyclines in an ablative regimen
in a cumulative dose of 100 mg m-2 may lead to 3% CHF
(Shenkenberg and Von Hoff, 1986). In the study of Bowers et al
(1993), 44 breast cancer patients were treated with escalating
doses of mitoxantrone in combination with 900 mg m-2 thiotepa
after pretreatment with 160-492 mg ni-2 doxorubicin. No acute
cardiotoxicity was observed using 50 mg m-2 mitoxantrone in 13
patients whereas, after 60 mg m-2 mitoxantrone, CHF occurred in
4 out of 31 patients (13%). One patient developed acute peri-
carditis and fourpatients had a . 10% decline in LVEF, amounting
to an overall incidence of acute cardiotoxicity of 29% (Bowers
et al, 1993). In the present study, we found that life-threatening
cardiotoxicity is a rare complication and late subclinical cardio-
toxicity was found in 4 of 27 evaluated patients at a median 2
years' follow-up, which occurred in all ablative regimens and was
not restricted to a particular schedule. The estimated percentage of
patients free ofcardiac dysfunction, including the two clinical and
four subclinical events, at 5 years is 94% (95% CI 88-100%) and
at 7 years 78% (95% CI 61-95%). These results are hamperedby a
limited follow-up and a small number of events, although an
increasing incidence ofcardiac dysfunction at longer follow-up is
suggested. Important is the recognition that the patients treated
with intensive chemotherapy are, in general, young adults without
a pre-existent cardiac history. Because ofthe curative intent ofthe
intensive treatment, the evaluation of cardiotoxicity is of impor-
tance for the future quality of life of these patients. The risk of
long-term cardiotoxicity is especially important in the adjuvant
setting and is much more ofa theoretical concern in the therapy of
metastatic disease as, if these patients should live long enough to
experience suchlateeffects, this wouldberegarded as avictory for
the treatment.
Inconclusion, thus far, the low incidence ofclinical and subclin-
ical cardiotoxicity in adult breast cancer patients does not hamper
the use of intensive chemotherapy combined with radiotherapy in
patients who would otherwise have a poor chance ofsurvival.
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